dEjournals Home Page
Régiókutatás Szemle
Current
Archives Fortcoming Articles Search
Register Login

Régiókutatás Szemle

Vol. 8 No. 1 (2023)
Articles

Necessity of cooperation on pharmaceutical and biotechnology development processes in the Northern Great Plain region

Published:
2024-01-15
DOI Linkhttps://doi.org/10.30716/RSZ/1/4
Authors
Balázs Kiss,
Dávid Domonkos,
János Felföldi
View
pdf (Hungarian)
Keywords
pharmaceutical (red) biotechnology innovation clusters industrial cooperation business risk reduction
License

Copyright (c) 2024 Balázs Kiss, Dávid Domonkos, János Felföldi

Creative Commons License

This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.

How To Cite
Selected Style: APA
Kiss, B., Domonkos, D., & Felföldi, J. (2024). Necessity of cooperation on pharmaceutical and biotechnology development processes in the Northern Great Plain region. Régiókutatás Szemle, 8(1), 30-46. https://doi.org/10.30716/RSZ/1/4
Abstract

One of the leading sectors of the Hungarian Northern Great Plain region - a high capital-intensive, long-return, "high risk - high benefit" industry such as red biotechnology – was examined to see what impact its development might have and what expectations the various cooperation opportunities set for the value chain at different points. It can be stated that the industry has serious, decades-long roots in the region. At the same time, following the spiral of the "biotech industry" also comes with new challenges, and a modern, innovative university background is essential for the expansion of the sector and its establishment at all. In the 2020s, new competitors arrived, such as the vehicle and battery industries, which are also high value-added and innovation-intensive industries. In all these areas, industry clusters have been formed, with universities of the region as intellectual hubs. Along these lines, the innovation mechanisms and collaborations of the respective disciplines (biotechnology in this publication) have been renewed, modernised and strengthened, which is also important for managing risks.

References
  1. Aitken, M.,Kleinrock, M.,Simorellis, A.,Nass, D. (2019): The global use of medicine in 2019 and outlook to 2023. IQVIA WP.0075-1-01.2019, 60 p.
  2. Abdelmalki, L., Kirat, T. (1993): National policies devoted to technology and the environment in France: towards an integrative approach? in: Aicholzer, G.; Schienstock, G.; Gruyter, D.: Technology policy: towards an integration of social and ecological concerns, Institute für Höhrere Studien, Wien 1993.
  3. Antalóczy K. (1999): Privatizáció a gyógyszeriparban. GJW-Consultatio-ÁPV Rt., Budapest, 188 oldal,·ISBN: 9630393573
  4. Antalóczy K., Gáspár T.,Sass M. (2021): A gyógyszeripari értéklánc sajátosságai Magyarországon. Közgazdasági Szemle, LXVIII . évf., 2021. június (645–673. o.)
  5. Brennan, L., Rakhmatullin, R. (2015): Global Value Chains and smart specialisation strategy. Thematic work on the understanding of Global Value Chains and their analysis within the context of smart specialisation. Eur 27649 en, Publications office of the European Union, Luxembourg, https://doi.org/10.2791/44840.
  6. Buciuni, G., Pisano, G. (2021): Variety of Innovation in Global Value Chains, Journal of World Business, Volume 56, Issue 2, 2021, 101167, ISSN 1090-9516, https://doi.org/10.1016/j.jwb.2020.101167.
  7. Bud, R. (1989): History of 'biotechnology'. Nature 337, 10 (1989). https://doi.org/10.1038/337010a0
  8. Cockburn, I., Henderson, R., Orsenigo, L., Pisano, G.P. (1999): Pharmaceuticals and biotechnology, U.S. Industry in 2000: Studies in Competitive Performance, D. Mowery, ed. Washington, D.C.: National Academy Press, 1999.
  9. Cooke, P. (2003): Biotechnology clusters, ’Big Pharma’ and the knowledge-driven economy, Int. J. Technology Management, 2003. Vol. 25, Nos. 1/2.,
  10. Cortright, J., Mayer, H. (2002): Signs of Life: The Growth of Biotechnology Centers in the U.S., Washington, D.C.: Brookings Institution Press 2002.
  11. DaSilva, E.J. (2004): The Colours of Biotechnology: Science, Development and Humankind. Electronic Journal of Biotechnology. Vol 7, No 3, 2004.
  12. Domonkos, D. (2012): Bizonytalanság-kezelés és innováció az egészségügyi (piros) biotechnológiai iparban. Doktori értekezés, BME, Budapest.
  13. de Backer, K., Miroudot, S. (2013): Mapping Chains. OECD trade policy papers, no. 159. OECD Publishing, Paris. https://doi.org/10.1787/5k3v1trgnbr4-en
  14. Dufourt, D. (1991): Les politiques technologiques une nouvelle rationalité de l'intervention publique dans systéme productif. in.: De Brandt, J.; Foray, D. (ed.): L'Évaluation Économique de la Recherche et du Changement Technique, Editions du CNRS, Paris, 1991.
  15. Feldman, M. (2003): The locational dynamics of the US biotech industry: Knowledge externalities and the anchor hypothesis, Industry and Innovation, 2003. Volume 10, Issue 3.
  16. Frigyesi V. (1989): A biotechnológia fejlődésének gazdasági feltételei, Külgazdaság, 1989. Volume11.
  17. Gorry, P. 2022. "Drug shortages, APIs supply & Pharma Global Value Chain," Post-Print hal-03737014, HAL.
  18. Goujon, P. (2001): From buiotechnology to Genomes. World Scientific Publishing Ltd. Singapore, 2001.
  19. Green, K. (1991): Shaping Technologies and Shaping Markets, Technology Analysis & Strategic Management, Vol.3, No.1. 1991.
  20. https://adoc.pub/13-korai-fazisu-kollaborativ-kutatasok-a-gyogyszeriparban-be.html
  21. I1: https://www.labiotech.eu/best-biotech/hungary-top-biotech-companies/ (2023)
  22. I2: https://unideb.hu/klaszterek (2023)
  23. I3: https://www.iqvia.com/insights/the-iqvia-institute/reports/the-global-use-of-medicines-2023 (2023)
  24. I4: https://www.gedeonrichter.com/-/media/sites/hq/documents/investors/presentations/hu/2023/prezentacio_2023_q1_hu_richter.pdf?rev=1f703da15b8f452f82fa8624f6905524&hash=1208A8FF3DE5D4C8BFC68DE0EEF23201 (2023)
  25. I5: https://www.haon.hu/helyi-kozelet/2023/06/a-hazai-biotechnologia-ipar-nelkulozhetetlen-reszeve-valt-a-debreceni-egyetem-haon (2023)
  26. Jacot, J.H. (1991): Kutatási és műszaki fejlesztési politika Franciaországban (1945-1990), Ipargazdasági Szemle 1991. 1.
  27. Joly, P-B. (1992): Organisational learning, diversity and interactions in a sectoral innovation system. INRA/SERD, Grenoble 1992.
  28. Kenney, M. (1986): Biotechnology: The University-Industrial Complex, New Haven, CT: Yale University Press, 1986.
  29. Kersan-Škabić. I., Belullo A. (2021): The Characteristics of Regional Value Chains in the Sector of Chemicals and Pharmaceutical Products in the EU. Economies. 2021; 9(4):167. https://doi.org/10.3390/economies9040167
  30. Longworth, R. C. (2006): Growing the Nation’s Bioscience Sector: State Bioscience Initiatives Battelle Technology Partnership Practice, SSTI.,2006.
  31. Lundvall, B.A. (1988): Innovation as an interactive process: from user-producer interaction to the national system of innovation. in: Dosi G.; Freeman, C.; Nelson, R.; Silverberg, G.; Soete, L.(ed.): Technical Change and Economic Theory. Pinter Publishers, London, New York, 1988.
  32. Magee, M. (2008): Health Politics, Spencer Books, 2008.
  33. McKelvey, M. (1991): How do National Systems of Innovation Differ?: A Critical Analysis of Porter, Freeman, Lundwall and Nelson. in: Hodgson, G.M.; Screpanti, E. (eds.) Rethinking Economics. Markets, Technology and Economic Evolution. Edward Elgar, Aldersot, Vermont, 1991.
  34. Medina, A., Thompson, D., Spinoglio, M., Magalhaes, H., Esteves, S., Pinho, F., Rocha, F., Bilsen, V., Debergh, P., Greeven, S., Kretz, D., Stehrer, R., Hanz-Weiss, D., Siedelschlag, I., Di Ubaldo, M., Studnicka, Z., Szalavetz, A., Sass, M. (2017): Study on investment needs and obstacles along industrial value chains. European commission, Brussel, https://op.europa.eu/hu/publication-detail/-/ publication/959cbc1d-ce72-11e7-a5d5-01aa75ed71a1.
  35. Orsenigo, L. (1989): Emergence of Biotechnology: Institutions and Markets in Industrial Innovation, Pinter Publishers, 1989.
  36. Pásztor G. Zs. (2010): Korai fázisú kollaboratív kutatások a gyógyszeriparban. https://adoc.pub/13-korai-fazisu-kollaborativ-kutatasok-a-gyogyszeriparban-be.html
  37. Spalding, B.J. (1991): It's about the time, Turning promise into reality,. Bio/Technology , November, 1991.
  38. Tömöri, G., Bács, Z., Felföldi, J., Orbán, I. (2022): Impact of Pharmaceutical R&D Activity on Financial Flexibility and Bargaining Power. Economies 2022, 10, 277. https://doi.org/10.3390/economies10110277
  39. Walsh, V. (1984): Invention and innovation in the chemical industry: Demand-pull or discovery-push, Research Policy, 1984.
  40. Yousuf, A., Lorestani, Z. V., Felfoldi, J., Zatonatska, T., Kozlovskyi, S., Dluhopolskyi, O. (2021b). Companies performance management: the role of operational flexibility. Marketing and Management of Innovations, 1, 30-37. https://doi.org/10.21272/mmi.2021.1-03
  41. Yousuf, A.; Lorestani, V.Z.; Oláh, J.; Felföldi, J. (2021a): Does Uncertainty Moderate the Relationship between Strategic Flexibility and Companies’ Performance? Evidence from Small and Medium Pharmaceutical Companies in Iran. Sustainability 2021, 13, 9157. https://doi.org/10.3390/su13169157
  42. Yousuf, A., Hossam, H., Felföldi, J., (2020): How Strategic Flexibility and Market Orientation affect Companies’ Performance? Evidence from Jordanian Pharmaceutical Companies (September 12, 2020). International Conference on Business Management, Innovation & Sustainability (ICBMIS) 2020, Available at SSRN: https://ssrn.com/abstract=3708868 or http://dx.doi.org/10.2139/ssrn.3708868
  43. Yousuf,A., Haddad, H., Pakurár, M., Kozlovskyi, S., Mohylova, A., Shlapak, O., Felföldi, J. (2019): The Effect of Operational Flexibility on Performance: A Field Study on Small and Medium-sized Industrial Companies in Jordan/ Montenegrin Journal of Economics, Vol. 15, No. 1 (2019), 047-060 DOI: 10.14254/1800-5845/2019.15-1.4
Database Logos
DOAJ ProQuest MTMT SHERPA EIRHPLUS EBSCO CROSSREF